<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129356">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797276</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 420-05</org_study_id>
    <nct_id>NCT01797276</nct_id>
  </id_info>
  <brief_title>Dichloroacetate Treatment of CLA</brief_title>
  <acronym>CLA</acronym>
  <official_title>Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Open Label</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to evaluate the safety of Dichloroacetate in children and adults with
      congenital lactic acidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to continue evaluating the chronic safety of dichloroacetate (DCA)
      as a potential treatment for patients with certain heretofore untreatable forms of
      congenital lactic acidosis. Adverse events will be used to evaluate this outcome.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Efficacy of Dichloroacetate in Patients with Congenital Lactic Acidosis</measure>
    <time_frame>up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the chronic safety of oral DCA in patients with CLA, as assessed by periodic clinical biochemical and nerve conduction evaluations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype</measure>
    <time_frame>up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A secondary objective is to determine the genotype of the subjects. It has been determined that genotype affects the metabolism of dichloroacetate. There are slow metabolizers and fast metabolizers.  It is important to know a person's genotype for dosing purposes.  Patients will have genotypes done.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Congenital Lactic Acidosis</condition>
  <arm_group>
    <arm_group_label>Dichloroacetate Administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are given the drug Dichloroacetate at a dose of 25mg/kg divided in two equal doses each day. They will take this drug for an indefinite period of time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dichloroacetate</intervention_name>
    <description>Subjects are given DCA 25mg/kg in a divided dose twice a day. They have EEG's done and nerve conduction studies.</description>
    <arm_group_label>Dichloroacetate Administration</arm_group_label>
    <other_name>DCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of congenital lactic acidosis including pyruvate dehydrogenase complex,

          -  Complexes 1-4, and

          -  Melas

        Exclusion Criteria:

          -  Intolerance to DCA
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter W. Stacpoole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Box 200226</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 13, 2013</lastchanged_date>
  <firstreceived_date>February 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dichloroacetate</keyword>
  <keyword>DCA</keyword>
  <keyword>CLA</keyword>
  <keyword>acidosis</keyword>
  <keyword>orphan disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Acidosis, Lactic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
